KR100540854B1 - Whitening cosmetic composition comprising phytolite and lactate - Google Patents
Whitening cosmetic composition comprising phytolite and lactate Download PDFInfo
- Publication number
- KR100540854B1 KR100540854B1 KR1020030018519A KR20030018519A KR100540854B1 KR 100540854 B1 KR100540854 B1 KR 100540854B1 KR 1020030018519 A KR1020030018519 A KR 1020030018519A KR 20030018519 A KR20030018519 A KR 20030018519A KR 100540854 B1 KR100540854 B1 KR 100540854B1
- Authority
- KR
- South Korea
- Prior art keywords
- cosmetic composition
- whitening
- lactate
- phytolite
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000002087 whitening effect Effects 0.000 title claims abstract description 50
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 239000002537 cosmetic Substances 0.000 title claims abstract description 40
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 title claims abstract description 24
- 229940001447 lactate Drugs 0.000 claims abstract description 23
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000001540 sodium lactate Substances 0.000 claims abstract description 20
- 229940005581 sodium lactate Drugs 0.000 claims abstract description 20
- 235000011088 sodium lactate Nutrition 0.000 claims abstract description 20
- 206010040880 Skin irritation Diseases 0.000 claims abstract description 16
- 231100000475 skin irritation Toxicity 0.000 claims abstract description 16
- 230000036556 skin irritation Effects 0.000 claims abstract description 16
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 239000000284 extract Substances 0.000 claims description 31
- 235000013399 edible fruits Nutrition 0.000 claims description 13
- 240000008067 Cucumis sativus Species 0.000 claims description 11
- 244000141359 Malus pumila Species 0.000 claims description 10
- 235000011430 Malus pumila Nutrition 0.000 claims description 10
- 235000015103 Malus silvestris Nutrition 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 7
- 239000000839 emulsion Substances 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 4
- 235000009849 Cucumis sativus Nutrition 0.000 claims description 3
- 240000004534 Scutellaria baicalensis Species 0.000 claims description 3
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims description 3
- 244000269722 Thea sinensis Species 0.000 claims description 3
- 235000006468 Thea sinensis Nutrition 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000006072 paste Substances 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000000344 soap Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- -1 phytolite Chemical compound 0.000 abstract description 12
- 230000002079 cooperative effect Effects 0.000 abstract description 3
- 230000000116 mitigating effect Effects 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 33
- 210000003491 skin Anatomy 0.000 description 26
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 102000003425 Tyrosinase Human genes 0.000 description 9
- 108060008724 Tyrosinase Proteins 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 235000018597 common camellia Nutrition 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 240000001548 Camellia japonica Species 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000008099 melanin synthesis Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 229960000271 arbutin Drugs 0.000 description 3
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 3
- 230000009931 harmful effect Effects 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 3
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 3
- 229960004705 kojic acid Drugs 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical group C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 2
- 240000000912 Macadamia tetraphylla Species 0.000 description 2
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 230000003061 melanogenesis Effects 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 239000010466 nut oil Substances 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 229940113124 polysorbate 60 Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 241000209507 Camellia Species 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 244000078534 Vaccinium myrtillus Species 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 231100000332 physical toxicant Toxicity 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B19/00—Layered products comprising a layer of natural mineral fibres or particles, e.g. asbestos, mica
- B32B19/06—Layered products comprising a layer of natural mineral fibres or particles, e.g. asbestos, mica next to a fibrous or filamentary layer
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B7/00—Layered products characterised by the relation between layers; Layered products characterised by the relative orientation of features between layers, or by the relative values of a measurable parameter between layers, i.e. products comprising layers having different physical, chemical or physicochemical properties; Layered products characterised by the interconnection of layers
- B32B7/04—Interconnection of layers
- B32B7/12—Interconnection of layers using interposed adhesives or interposed materials with bonding properties
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09J—ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
- C09J175/00—Adhesives based on polyureas or polyurethanes; Adhesives based on derivatives of such polymers
- C09J175/04—Polyurethanes
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09J—ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
- C09J5/00—Adhesive processes in general; Adhesive processes not provided for elsewhere, e.g. relating to primers
- C09J5/08—Adhesive processes in general; Adhesive processes not provided for elsewhere, e.g. relating to primers using foamed adhesives
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 미백 화장료 조성물에 관한 것으로서, 보다 상세하게는 미백에 대한 유효 성분으로서 락테이트 및 피토라이트를 포함하는 미백 화장료 조성물에 관한 것이다. 본 발명의 미백 화장료 조성물은 락테이트 및 피토라이트의 공동적인 작용에 의해 미백 효과가 최대화될 뿐만 아니라, 락테이트에 의해 유발되는 피부 자극을 피토라이트가 유효하게 완화하여 피부 안정성의 측면에서도 크게 개선된다.The present invention relates to a whitening cosmetic composition, and more particularly to a whitening cosmetic composition comprising lactate and phyrite as active ingredients for whitening. The whitening cosmetic composition of the present invention not only maximizes the whitening effect by the cooperative action of lactate and phyrite, but also significantly improves the skin stability by effectively mitigating the skin irritation caused by lactate. .
화장료, 미백, 락테이트, 피토라이트, 소듐락테이트Cosmetics, whitening, lactate, phytolite, sodium lactate
Description
본 발명은 미백 화장료 조성물에 관한 것으로서, 보다 상세하게는 미백 유효성분으로 락테이트 및 피토라이트 (Phytolight)를 포함하는 미백 화장료 조성물에 관한 것이다.The present invention relates to a whitening cosmetic composition, and more particularly to a whitening cosmetic composition comprising lactate and phytolight as a whitening active ingredient.
사람의 피부, 모발, 눈 등에서 발현하는 색은 멜라닌, 카로틴 및 헤모글로빈에 의해 결정되어지며 특히 피부에 있어 색깔을 결정하는 가장 중요한 요인은 멜라닌으로 멜라닌의 양과 성질 그리고 분포의 정도에 따라 피부색이 결정된다. The color of human skin, hair, and eyes is determined by melanin, carotene and hemoglobin, and the most important factor in determining the color of skin is melanin. The color of skin depends on the amount, nature and distribution of melanin. .
인간에 있어 피부나 모발의 색소는 햇빛 (특히 자외선)의 유해한 영향으로부터 보호해주는 역할을 한다. 예를 들어, 색소가 부족한 사람은 햇빛에 매우 민감하여 화상을 입기 쉬우며 어린 나이에도 피부암 발생확률이 높다. 단파장의 자외선 (290-320 nm) 및 발암 물질은 피부에서 유해 라디칼을 형성하는데, 이 산소 라 디칼이 피부 세포를 공격하여 피부를 노화시키는 것으로 알려져 있다.In humans, pigments in the skin and hair protect against the harmful effects of sunlight (especially ultraviolet rays). For example, people with poor pigmentation are very sensitive to sunlight and are prone to burns and have a high probability of developing skin cancer even at a young age. Short wavelength ultraviolet light (290-320 nm) and carcinogens form harmful radicals in the skin, which are known to attack skin cells and age the skin.
멜라닌의 주요한 기능은 이러한 유해 라디칼을 제거하여 이에 의한 손상으로부터 피부를 보호하는 것이다. 그러므로 멜라닌이 많다는 것은 물리적, 화학적 독성물질로부터 피부를 보호하기 위한 효과적인 대응체계를 가지고 있다는 것을 의미한다. 이러한 멜라닌의 생성을 촉진하는 요인들로서는 햇빛 (특히 자외선)뿐만 아니라 에스트로겐, 프로스타글란딘 등과 같은 호르몬이 있다. The main function of melanin is to remove these harmful radicals and protect the skin from the damage thereby. Therefore, high levels of melanin mean that it has an effective response system to protect the skin from physical and chemical toxicants. Factors that promote the production of melanin include sunlight (particularly ultraviolet rays) as well as hormones such as estrogen and prostaglandins.
멜라닌은 햇빛(자외선)에 의해 멜라노사이트에서 티로신이 티로시나아제라는 효소에 의해 도파와 도파크롬으로 변환된 뒤 복잡한 산화와 축합 반응을 거쳐 생성된다. 생성된 멜라닌은 피부 세포에 전달되고 표피 박리와 함께 멜라닌이 상실되어 소멸되는 순환 작용을 보인다. 멜라닌 생성 메타니즘의 특징은 티로시나아제라는 단 한 개의 효소가 관여하는 것으로 티로시나아제 활성을 억제하여 멜라닌 생성을 막아줌으로서 미백효과를 기대할 수 있다. Melanin is produced by complex oxidation and condensation reactions of melanocytes in the melanosite by sunlight (ultraviolet rays), which are converted to dopa and dopachrome by an enzyme called tyrosinase. The resulting melanin is delivered to the skin cells and exhibits a circulating action in which the melanin is lost and disappeared along with epidermal detachment. The melanin-generating mechanism is characterized by the involvement of only one enzyme, tyrosinase, which can be expected to whiten by inhibiting tyrosinase activity and preventing melanin production.
미백 화장품에 있어 멜라닌 생성을 억제하는 방법은 크게 다음과 같이 나눌 수 있다. 한가지 방법은 멜라닌 생성의 주원인인 자외선을 차단하여 제거하는 것으로써, 이 방법은 화장품 조성물에 광 산란제 또는 광 차단제를 함유시켜 좋은 결과를 기대할 수 있다. 또 한가지 방법은 글루코사민과 같이 티로시나아제가 활성을 나타내기 위해 필요한 코어 탄수화물의 합성을 저해함으로써, 멜라닌 생성을 억제시키는 것이다. 효소산 (코직산) 또는 알부틴과 같이 멜라닌 생성에 관여하는 티로시나아제의 기능을 방해하는 방법도 있다. 또 다른 방법은 하이드로퀴논과 같이 멜라닌을 생성하는 세포인 멜라노사이트에 대하여 특이적인 독성을 가지고 있 어 세포 분열을 방해하는 방법이다. 비타민 C와 같이 티로신이 도파와 도파크롬을 거쳐 복잡한 산화와 축합반응을 거치는 동안에 강한 항산화 효과를 발휘하여 미백효과를 기대하는 방법도 있다.The method of inhibiting melanin production in whitening cosmetics can be divided into the following. One method is to block and remove ultraviolet rays, which are the main cause of melanin production, and this method can be expected to include good light scattering agent or light blocking agent in the cosmetic composition. Another method is to inhibit melanin production by inhibiting the synthesis of core carbohydrates required for tyrosinase to be active, such as glucosamine. There are also methods that interfere with the function of tyrosinase involved in melanogenesis, such as enzyme acid (kojic acid) or arbutin. Another method is to disrupt cell division because it has specific toxicity against melanocytes, which are melanin-producing cells such as hydroquinone. Like vitamin C, there is also a way to expect whitening effect by showing strong antioxidant effect during tyrosine through complex oxidation and condensation reaction through dopa and dopachrome.
지금까지 아스코르빈산 (일본 특개평 4-9320)의 사용으로 미백효과를 볼 수 있는 방법이 제시되어 있다. 그러나 아스코르빈산 자체가 처방계 중에서 상 안정성이 나빠 시간이 경과하면서 그 유효 성분의 활성도가 떨어지므로 최근에는 캡슐 및 리포좀으로 안정화시키는 등의 다양한 방법이 제기되고 있으나, 아직 뚜렷한 안정화 방법을 제시하지 못하고 있다. To date, the use of ascorbic acid (Japanese Patent Application Laid-Open No. 4-9320) has been proposed to show a whitening effect. However, since ascorbic acid itself has poor phase stability in the prescription system, the active ingredient's activity decreases with time, and various methods such as stabilization with capsules and liposomes have recently been proposed. have.
또 다른 미백 화장료 특히 하이드로퀴논 (일본 특개평 6-192062)은 그 효과가 우수하나, 발암성 물질이므로 화장품으로서의 사용에 제한을 받고 있다. 또 다른 특허 코직산 (일본 특개평 56-7710)은 티로신이 도파와 도파크롬으로 변해 가는 중간에 관여하는 유일한 효소인 티로시나아제의 저해 능력이 탁월하여 미백효과가 우수하게 나타나지만 처방계 중에서 갈색으로 변화하는 등 안전성 측면에서 재고되고 있다. Another whitening cosmetic, especially hydroquinone (Japanese Patent Laid-Open No. 6-192062), has an excellent effect, but is limited to its use as a cosmetic since it is a carcinogenic substance. Another patent kojic acid (Japanese Patent Laid-Open No. 56-7710) has excellent whitening effect due to its excellent inhibitory ability of tyrosinase, the only enzyme involved in the transition of tyrosine to dopa and dopachrome. It is being reconsidered in terms of safety.
또 다른 특허 알부틴 (일본 특개평 4-9315)은 천연 식물 물질인 고산지대의 월귤나무에서 추출하거나 합성을 통하여 얻을 수 있으며, 코직산과 마찬가지로 티로시나아제에 대한 억제 능력이 검증되고 있으나, 알부틴 자체가 하이드로퀴논에 당이 붙어있는 상태로 화장료로 적용시 피부 효소에 의해 당이 분리된 후 하이드로퀴논에 의한 피부 자극이 우려되기도 한다. Another patent arbutin (Japanese Patent Application Laid-Open No. 4-9315) can be obtained from or extracted from bilberry, which is a natural plant material, and is synthesized. As with kojic acid, the ability to inhibit tyrosinase has been proven, but arbutin itself is hydro When sugars are attached to quinones and applied as cosmetics, the skin may be irritated by hydroquinone after sugars are separated by skin enzymes.
종래의 이런 문제점 때문에 많은 천연물을 이용하여 안전을 개선한 미백 원 료들의 개발이 시도되고 있다.Due to this problem in the related art, the development of whitening raw materials which improve safety using many natural products has been attempted.
이에, 본 발명자들은 피부자극이 적고 미백 효과를 상승시킬 수 있는 새로운 화장료 조성물을 개발하고자 예의 연구 노력한 결과, 락테이트 및 피토라이트의 혼합물을 이용하는 경우에는 락테이트에 의한 피부자극이 크게 완화되고, 미백효과가 크게 증가함을 확인함으로써, 본 발명을 완성하게 되었다.Accordingly, the present inventors have diligently researched to develop a new cosmetic composition that can reduce skin irritation and enhance the whitening effect. As a result, when using a mixture of lactate and phyrite, the skin irritation caused by lactate is greatly alleviated. By confirming that the effect greatly increased, the present invention was completed.
따라서, 본 발명의 목적은 피부자극이 완화되고 미백효과가 개선된 미백 화장료 조성물을 제공하는 데 있다.
Accordingly, it is an object of the present invention to provide a whitening cosmetic composition that is alleviated skin irritation and improved whitening effect.
본 발명의 다른 목적 및 이점은 하기의 발명의 상세한 설명 및 청구범위에 의해 보다 명확하게 된다.
Other objects and advantages of the present invention will become apparent from the following detailed description and claims.
본 발명의 양태에 따르면, 본 발명은 미백에 대한 유효 성분으로서 락테이트 및 피토라이트를 포함하는 미백 화장료 조성물을 제공한다.According to an aspect of the present invention, the present invention provides a whitening cosmetic composition comprising lactate and phyrite as active ingredients for whitening.
본 발명의 화장료 조성물에서, 미백에 대한 유효 성분으로 이용되는 락테이트는 미백 화장료에 많이 사용되어 왔던 것으로서, 표피에 침착되어 얼굴색을 칙칙하게 만드는 각질을 박리시켜 (Peeling effect) 미백 효과를 나타낸다. 이러한 락테이트는 분자량이 작아 피부 속에 침투가 용이하다는 장점이 있으나, 지속적인 사용시 피부안전성 부분에서 홍반, 가려움 등과 같은 피부자극을 유발하는 문제점이 있다. In the cosmetic composition of the present invention, lactate used as an active ingredient for whitening has been widely used in whitening cosmetics, and has a whitening effect by peeling off keratin that is deposited on the epidermis and makes the face color dull. Such lactate has the advantage of easy penetration into the skin due to its low molecular weight, but there is a problem of causing skin irritation such as erythema and itching in the skin safety part during continuous use.
이에, 본 발명자들은 피토라이트를 피부안전성 및 미백의 효과를 개선하기 위하여 화장료에 적용함에 있어서 피부의 각질을 박리시키는 락테이트와 함께 배합하여 사용할 경우 미백효과의 상승 작용과 피부 안전성이 증가하는 것을 발견하였다.Accordingly, the present inventors have found that the synergistic effect of the whitening effect and the skin safety are increased when the phytolite is used in combination with lactate to exfoliate the keratin of the skin in the application to the cosmetic to improve the effect of skin safety and whitening. It was.
본 발명의 화장료 조성물에서, 또 다른 유효성분으로서의 피토라이트 (phytolight)는 식물이라는 의미의 접두사 "phyto-"에 미백 작용을 한다는 의미의 "light"를 합하여 만든 용어로서, 본 명세서에서는 미백 작용을 나타내는 사과 추출물, 황금 뿌리 추출물, 동백나무 잎 추출물, 오이 추출물 또는 상기 추출물의 혼합물을 의미한다.In the cosmetic composition of the present invention, phytolight as another active ingredient (phytolight) is a term made by combining the prefix "phyto-" meaning plant and "light" meaning whitening action. Means apple extract, golden root extract, camellia leaf extract, cucumber extract or a mixture of said extracts.
본 발명의 화장료 조성물에 포함되는 식물 추출물은 다양한 추출방법으로 얻을 수 있으며, 수성 또는 유기용매를 가하여 추출하여 얻을 수 있다. 구체적으로는, 물, 탄소수 1-4개의 무수 또는 함수 저급 알코올, 아세톤, 에틸아세테이트, 부틸아세테이트, 클로로포름, 1,3-부틸렌글리콜 등을 가하여 추출물을 수득하는 방법을 사용함이 바람직하다.The plant extract included in the cosmetic composition of the present invention can be obtained by various extraction methods, and can be obtained by adding an aqueous or organic solvent. Specifically, it is preferable to use a method of obtaining an extract by adding water, anhydrous or hydrous lower alcohol having 1 to 4 carbon atoms, acetone, ethyl acetate, butyl acetate, chloroform, 1,3-butylene glycol, and the like.
본 발명의 구현예에 따르면, 상기 피토라이트는 상기한 추출물 1종을 포함할 수 있으나, 보다 바람직하게는 상기한 추출물 2종 이상의 조합물을 포함한다.According to an embodiment of the present invention, the phytolite may include one of the above extracts, and more preferably includes a combination of two or more of the above extracts.
본 발명의 피토라이트에 포함되는 사과 추출물은 사과 나무의 다양한 기관 ( 꽃, 과실, 줄기, 뿌리, 잎 등)으로부터 제조될 수 있으나, 바람직하게는 사과 과실로부터 추출된 것이다. 사과 추출물의 함량은 전체 피토라이트에 대하여 0.001-10 중량%이 바람직하다.Apple extract included in the phytolite of the present invention may be prepared from various organs (flowers, fruits, stems, roots, leaves, etc.) of the apple tree, but is preferably extracted from apple fruit. The content of the apple extract is preferably 0.001-10% by weight based on the total phyrite.
본 발명의 피토라이트에 포함되는 황금 추출물은 황금의 다양한 기관 (꽃, 과실, 줄기, 뿌리, 잎 등)으로부터 제조될 수 있으나, 바람직하게는 황금의 뿌리로부터 추출된 것이다. 황금 뿌리 추출물의 함량은 전체 피토라이트에 대하여 0.001-10 중량%이 바람직하다.The golden extract included in the phytolite of the present invention may be prepared from various organs of gold (flowers, fruits, stems, roots, leaves, etc.), but is preferably extracted from the golden roots. The content of the golden root extract is preferably 0.001-10% by weight based on the total phytolite.
본 발명의 피토라이트에 포함되는 동백나무 추출물은 동백나무의 다양한 기관 (꽃, 과실, 줄기, 뿌리, 잎 등)으로부터 제조될 수 있으나, 바람직하게는 동백나무의 잎으로부터 추출된 것이다. 동백 나무 잎의 함량은 전체 피토라이트에 대하여 0.001-10 중량%이 바람직하다.Camellia extract included in the phytolite of the present invention may be prepared from various organs (flowers, fruits, stems, roots, leaves, etc.) of the camellia, but is preferably extracted from the leaves of the camellia. The content of camellia leaves is preferably 0.001-10% by weight based on the total phyrite.
본 발명의 피토라이트에 포함되는 오이 추출물은 오이의 다양한 기관 (꽃, 과실, 줄기, 뿌리, 잎 등)으로부터 제조될 수 있으나, 바람직하게는 오이의 과실로부터 추출된 것이다. 오이 과실의 함량은 전체 피토라이트에 대하여 0.001-10 중량%가 바람직하다.Cucumber extract included in the phytolite of the present invention may be prepared from various organs (flowers, fruits, stems, roots, leaves, etc.) of the cucumber, but is preferably extracted from the fruit of the cucumber. The content of cucumber fruit is preferably 0.001-10% by weight based on the total phyrite.
본 발명의 바람직한 구현예에 따르면, 본 발명의 피토라이트에는 EDTA가 추가적으로 포함될 수 있다. EDTA는 본 발명의 피토라이트에서 멜라닌 생성 과정 중 타이로신을 산화시키는 데 필요한 금속성 보조 인자인 구리 이온과 결합함으로써 티로시나아제를 억제하는 기능을 한다. 보다 바람직하게는 EDTA는 안정한 염의 형태, 예컨대 다이소듐 EDTA이다.According to a preferred embodiment of the present invention, the phyrite of the present invention may additionally include EDTA. EDTA functions to inhibit tyrosinase by binding to copper ions, which is a metallic cofactor required to oxidize tyrosine during melanogenesis in phyrite. More preferably EDTA is in the form of a stable salt, such as disodium EDTA.
따라서, 본 발명에서 이용되는 피토라이트의 가장 바람직한 형태는 사과추출물 (Pyrus Malus Fruit Extract), 황금 뿌리 추출물 (Scutellaria Baicalensis Root Extract), 동백나무잎추출물 (Camellia Sinensis Leaf Extract), 오이추출물(Cucumis Sativus Fruit Extract) 및 EDTA-2Na의 혼합물이다. Thus, the most preferred form of phytolite used in the present invention is apple extract ( Pyrus Malus Fruit Extract), Scutellaria Baicalensis Root Extract, Camellia Sinensis Leaf Extract, Cucumber Extract ( Cucumis Sativus Fruit) Extract) and EDTA-2Na.
상기 피토라이트는 식물 추출물이기 때문에, 피부에 대한 안전성이 우수할 뿐 만 아니라 티로시나아제 저해능이 탁월하여 피부를 하얗고 투명하게 가꿔주는 역할을 한다. 더불어, 본 발명자들은 피토라이트가 락테이트에 의한 피부 자극을 완화하는 작용을 한다는 것을 발견하였다.Since the phytolite is a plant extract, it not only has excellent safety for the skin but also has an excellent tyrosinase inhibitory ability to serve to make the skin white and transparent. In addition, the inventors have found that phytolite acts to alleviate skin irritation caused by lactate.
이는 저분자인 락테이트가 피부의 각질을 제거하여 피부각질층에 자극을 발생시킬 때, 천연물인 피토라이트가 자극을 완화하면서 피부속에 침투되어 미백효과의 상승작용이 발생되는 것으로 판단된다.It is believed that when low-molecular lactate removes dead skin cells and causes irritation of the stratum corneum, natural phytolite penetrates into the skin while alleviating the irritation, causing synergism of the whitening effect.
따라서, 본 발명의 화장료 조성물에서, 피토라이트는 미백 작용과 락테이트에 의한 피부 자극을 완화시키는 작용을 동시에 한다.Therefore, in the cosmetic composition of the present invention, phytolite has a function of alleviating skin irritation by whitening and lactate.
본 발명의 조성물에 이용되는 락테이트는 다양한 염의 형태를 갖을 수 있으나, 가장 바람직하게는 소듐락테이트이다. 또한, 소듐락테이트는 바람직하게는 50-70% 소듐락테이트, 보다 바람직하게는 60% 소듐락테이트가 이용된다.The lactates used in the compositions of the present invention may take the form of various salts, most preferably sodium lactate. Also, sodium lactate is preferably 50-70% sodium lactate, more preferably 60% sodium lactate.
본 발명의 바람직한 구현예에 따르면, 상기 소듐락테이트 및 피토라이트의 함량은 전체 조성물을 기준으로 하여 각각 1-20 중량% 및 0.001-10 중량%이다. 보다 바람직하게는, 상기 소듐락테이트 및 피토라이트의 함량은 각각 10-18 중량% 및 1-5 중량%이다.According to a preferred embodiment of the present invention, the content of sodium lactate and phyrite is 1-20% by weight and 0.001-10% by weight, respectively, based on the total composition. More preferably, the content of sodium lactate and phyrite is 10-18% by weight and 1-5% by weight, respectively.
본 발명의 화장품 조성물에 포함되는 성분은 유효 성분으로서의 락테이트 및 피토라이트 이외에 화장품 조성물에 통상적으로 이용되는 성분들을 포함하며, 예컨대 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 그리고 담체를 포함한다.The components included in the cosmetic composition of the present invention include components conventionally used in cosmetic compositions in addition to lactate and phyrite as active ingredients, and include, for example, conventional agents such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavorings. Adjuvants, and carriers.
본 발명의 미백용 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 유연 화장수, 영양 화장수, 영양 크림, 마사지 크림, 에센스, 아이 크림, 클렌징 크림, 클렌징 포옴, 클렌징 워터, 팩, 스프레이 또는 파우더의 제형으로 제조될 수 있다.The whitening composition of the present invention may be prepared in any formulation conventionally prepared in the art, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing It may be formulated as cleansing, oil, powder foundation, emulsion foundation, wax foundation, spray, and the like, but is not limited thereto. More specifically, it may be prepared in the form of a flexible lotion, nutrition lotion, nutrition cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray or powder.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, animal oils, vegetable oils, waxes, paraffins, starches, trachants, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicas, talc or zinc oxide may be used as carrier components. Can be.
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, in particular in the case of a spray, additionally chlorofluorohydrocarbon, propane Propellant such as butane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이 트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or emulsion, a solvent, solubilizer or emulsifier is used as the carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol , Fatty acid esters of 1,3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, liquid carrier diluents such as water, ethanol or propylene glycol, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystals Soluble cellulose, aluminum metahydroxy, bentonite, agar or tracant and the like can be used.
본 발명의 제형이 계면-활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is a surfactant-containing cleansing, the carrier component is an aliphatic alcohol sulfate, an aliphatic alcohol ether sulfate, a sulfosuccinic acid monoester, isethionate, an imidazolinium derivative, a methyltaurate, a sarcosinate, a fatty acid amide. Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
본 발명의 미백 화장료 조성물은 락테이트 및 피토라이트의 공동적인 작용에 의해 미백 효과가 최대화될 뿐만 아니라, 락테이트에 의해 유발되는 피부 자극을 피토라이트가 유효하게 완화하여 피부 안정성의 측면에서도 크게 개선된다.The whitening cosmetic composition of the present invention not only maximizes the whitening effect by the cooperative action of lactate and phyrite, but also significantly improves the skin stability by effectively mitigating the skin irritation caused by lactate. .
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로서, 본 발명의 요 지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only for illustrating the present invention in more detail, and the scope of the present invention is not limited by these examples according to the gist of the present invention to those skilled in the art. Will be self-evident.
제조예 1Preparation Example 1
하기 표 1의 조성을 갖는 피토라이트를 제조하였다:Phytolites having the composition of Table 1 were prepared:
처방예 1Prescription Example 1
본 발명의 60% 소듐락테이트와 피토라이트를 포함한 화장료 중 유연화장수(스킨)의 처방예는 다음과 같다: Prescription examples of softening water (skin) in cosmetics containing 60% sodium lactate and phytolite of the present invention are as follows:
처방예 2Prescription Example 2
본 발명의 60% 소듐락테이트와 피토라이트를 포함한 화장료 중 밀크로션의 처방예는 다음과 같다: Formulation examples of milk lotion in cosmetics containing 60% sodium lactate and phytolite of the present invention are as follows:
처방예 3Prescription Example 3
본 발명의 60% 소듐락테이트와 피토라이트를 포함한 화장료 중 영양크림의 처방예는 다음과 같다: Prescription examples of nutritional creams in cosmetics containing 60% sodium lactate and phytolite of the present invention are as follows:
미백효과와 피부 안전성을 측정하기 위하여, 실시예 1, 2 및 3과 비교예 1-9를 제조하였다. 처방의 특징에서 보듯이 소듐락테이트와 피토라이트를 각각 사용한 처방 그리고 사용하지 않은 처방을 비교예로 설정하였다. 상기의 실시예 및 비교예에 따라 제조된 화장료 조성물의 피부 안전성, 미백효과를 각각 측정하였다. In order to measure the whitening effect and skin safety, Examples 1, 2 and 3 and Comparative Examples 1-9 were prepared. As shown in the characteristics of the prescription, the prescription using sodium lactate and phytolite, respectively, and the unused prescription were set as comparative examples. Skin safety and whitening effect of the cosmetic composition prepared according to the above Examples and Comparative Examples were measured, respectively.
시험예 1: 피부 자극성 시험Test Example 1: Skin irritation test
상기 실시예 및 비교예에 따라 제조된 제품들의 피부 자극성을 알아보기 위하여, 건강한 성인 남·여 50명을 대상으로 양팔 하박부에 5 x 20 cm 부위에 각 시료의 일정양 (약 0.1g)을 24시간 첩포한 후, 제거하고 1시간, 24시간 경과한 다음 육안으로 피부 상태 변화를 판독하였으며, 그 결과를 표 2에 나타내었다. 판정기준 및 자극도 계산 방법은 다음과 같다: In order to determine the skin irritation of the products prepared according to the above examples and comparative examples, 50 healthy adults males and females were placed in a constant amount (about 0.1g) of each sample at 5 x 20 cm in the lower arm of both arms. After patching for 24 hours, the skin condition changes were visually read after 1 hour and 24 hours after removal, and the results are shown in Table 2. Criteria and stimulus calculation methods are as follows:
* 판정기준 ** Criteria *
- : 홍반이나 특이한 현상없음; +-: 주위보다 약간 붉어짐 -No erythema or unusual symptoms; +-: Slightly redder than the surroundings
+ : 주위보다 현저히 붉어짐 ++: 주위보다 심하게 붉어지고 부풀음 +: Significantly redder than surroundings ++: Severe reddening and swelling around
상기 표의 피부 자극성 시험결과에서 알 수 있듯이 실시예 1, 2 및 3이 비교예 1-9와 비교하여 보통의 자극도를 보임을 알 수 있다. 특히, 비교예 2, 5 및 8과 비교해서는 매우 낮은 자극도를 보였다.As can be seen from the skin irritation test results in the table, it can be seen that Examples 1, 2, and 3 show normal irritation degree compared to Comparative Examples 1-9. In particular, compared to Comparative Examples 2, 5, and 8 showed a very low degree of stimulation.
보다 상세하게는, 비교예 2, 5 및 8은 소듐락테이트를 포함하는 조성물로서, 이들은 소듐락테이트에 의해 유발되는 피부 자극도가 매우 크다 (각각 8.7, 6.7 및 6.0). 그러나, 본 발명의 실시예 1, 2 및 3의 결과를 보면, 소듐락테이트에 의한 피부 자극이 피토라이트에 의해 크게 감소되고 있음을 알 수 있다.More specifically, Comparative Examples 2, 5 and 8 are compositions comprising sodium lactate, which have a very high skin irritation caused by sodium lactate (8.7, 6.7 and 6.0, respectively). However, the results of Examples 1, 2 and 3 of the present invention, it can be seen that the skin irritation caused by sodium lactate is greatly reduced by phyrite.
따라서, 피토라이트는 화장료 조성물에서 소듐락테이트에 의한 피부 자극을 감소시키는 기능을 할 수 있음을 알 수 있다.Thus, it can be seen that phytolite may function to reduce skin irritation caused by sodium lactate in the cosmetic composition.
시험예 2: 미백 효과 측정Test Example 2: Measurement of Whitening Effect
19-40세의 한국여성의 지원자 30명을 대상으로 실시하였다. 특히 지원자의 여성의 피부가 검은 피부를 가진 여성을 대상으로 하였다. 측정 장비로는 Minolta CR 300을 사용하였으며 2달 동안 2주 간격으로 측정하였다. 측정 부위는 팔에다 9군데에 가로세로 1 cm씩 표시하고 꾸준히 각기 다른 처방 8군데 (실시예 2, 3 및 비교예 4-9)를 바르고 하나는 비교를 위하여 대조군 값으로 두었다. 대조군과의 차이를 표 6에 나타내었다.Thirty volunteers of Korean women aged 19-40 years old were selected. In particular, the women's skin of volunteers was targeted for women with dark skin. Minolta CR 300 was used as a measuring instrument and measured at 2 week intervals for 2 months. The measurement sites were marked with 1 cm of width and length on 9 arms, and 8 different prescriptions (Examples 2, 3 and Comparative Examples 4-9) were continuously applied and one was placed as a control value for comparison. The difference from the control is shown in Table 6.
표 6에서 알 수 있듯이, 8주 후의 ΔL 값이 실시예 2 및 3이 비교예 4-9들과 대조군에 비해 높다는 것을 알 수 있다. 즉, 피토라이트와 소듐락테이트를 포함하는 본 발명의 조성물은 종래의 미백 화장료 조성물과 비교하여 상당히 증가된 미백 효과를 갖고 있음을 알 수 있다.As can be seen from Table 6, it can be seen that the ΔL value after 8 weeks is higher in Examples 2 and 3 than Comparative Examples 4-9 and the control. That is, it can be seen that the composition of the present invention comprising phyrite and sodium lactate has a significantly increased whitening effect compared to conventional whitening cosmetic compositions.
이상에서 상세히 설명한 바와 같이, 본 발명은 미백에 대한 유효 성분으로서 락테이트 및 피토라이트를 포함하는 미백 화장료 조성물을 제공한다. 본 발명의 미백 화장료 조성물은 락테이트 및 피토라이트의 공동적인 작용에 의해 미백 효과가 최대화될 뿐만 아니라, 락테이트에 의해 유발되는 피부 자극을 피토라이트가 유효하게 완화하여 피부 안정성의 측면에서도 크게 개선된다.As described in detail above, the present invention provides a whitening cosmetic composition comprising lactate and phytolite as an active ingredient for whitening. The whitening cosmetic composition of the present invention not only maximizes the whitening effect by the cooperative action of lactate and phyrite, but also significantly improves the skin stability by effectively mitigating the skin irritation caused by lactate. .
Claims (7)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020030018519A KR100540854B1 (en) | 2003-03-25 | 2003-03-25 | Whitening cosmetic composition comprising phytolite and lactate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020030018519A KR100540854B1 (en) | 2003-03-25 | 2003-03-25 | Whitening cosmetic composition comprising phytolite and lactate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20040083843A KR20040083843A (en) | 2004-10-06 |
| KR100540854B1 true KR100540854B1 (en) | 2006-01-24 |
Family
ID=37367507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020030018519A Expired - Lifetime KR100540854B1 (en) | 2003-03-25 | 2003-03-25 | Whitening cosmetic composition comprising phytolite and lactate |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR100540854B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015160030A1 (en) * | 2014-04-15 | 2015-10-22 | 한국콜마주식회사 | Maackiasin having skin whitening activity and use thereof |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100829596B1 (en) * | 2006-02-22 | 2008-05-14 | 한국화학연구원 | Cucumber Herbal Extract with Antioxidant Activity |
| KR101671803B1 (en) * | 2015-10-02 | 2016-11-03 | 주식회사 베스트솔루션 | Cosmetic composition with the extract of Camellia japonica L. leaf |
| KR102710818B1 (en) * | 2021-01-28 | 2024-09-27 | 재단법인 경남항노화연구원 | Manufacturing method for skin whitening composition using Camellia flower and Camellia japonica leaf |
| KR102831553B1 (en) * | 2023-02-16 | 2025-07-09 | 주식회사 코리아나화장품 | Cosmetic compositions for brightening skin and shoothing skin comprising phytolight, lactate and boerhavia diffusa root extract as active ingredients |
-
2003
- 2003-03-25 KR KR1020030018519A patent/KR100540854B1/en not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015160030A1 (en) * | 2014-04-15 | 2015-10-22 | 한국콜마주식회사 | Maackiasin having skin whitening activity and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20040083843A (en) | 2004-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100855457B1 (en) | Cosmetic composition for skin whitening containing actin, actinigen or a mixture thereof as an active ingredient | |
| KR101551243B1 (en) | Cosmetic Composition for Skin Whitening Having Fomes Fomentarius | |
| KR101299024B1 (en) | Cosmetics composition for skin lightening color, antioxidantsand and method for preparing the same | |
| KR100540854B1 (en) | Whitening cosmetic composition comprising phytolite and lactate | |
| KR100530669B1 (en) | Cosmetic Compositions Comprising Lactate and Glycyrrhiza Uralensis Extracts for Skin Whitening | |
| KR20120009708A (en) | Composition for improving skin condition comprising afzelin as an active ingredient | |
| KR20080079016A (en) | Cosmetic composition for preventing skin aging containing eggplant extract of Magnolia sieboldii as an active ingredient | |
| KR100495454B1 (en) | Cosmetic Compositions for Skin-Whitening Comprising Phytolight as Active Ingredient | |
| KR100538078B1 (en) | Cosmetic Compositions Comprising Panax ginseng (C.A. MEY) Extract and Plant Extracts as Oriental Medicine for Preventing Skin Aging | |
| KR100678864B1 (en) | Cosmetic composition for skin whitening containing cheongung extract and carnitine as active ingredients | |
| KR100773863B1 (en) | Cosmetic composition for preventing skin aging and a method of manufacturing the same | |
| KR20130089559A (en) | Anti-aging composition | |
| KR101551240B1 (en) | Cosmetic Composition for Skin Whitening Having Kaempferia Parviflora | |
| KR101028238B1 (en) | A whitening cosmetic composition comprising birch, top and tall fortified extract | |
| KR101317433B1 (en) | The cosmetic composition for skin whitening comprising the mixture of extract of Hovenia dulcia, Platycodon grandiflorum, wheat bud and sage | |
| KR100795514B1 (en) | Skin whitening composition containing diosgenin | |
| KR100449345B1 (en) | Cosmetic Composition for Skin-Whitening Comprising Emblica officinalis Extract and Ramulus mori Extracts as Active Ingredients | |
| KR100744947B1 (en) | Cosmetic composition for skin whitening containing cheongung extract and protease as active ingredients | |
| KR102048713B1 (en) | cosmetics containing boswellic acid | |
| KR102831553B1 (en) | Cosmetic compositions for brightening skin and shoothing skin comprising phytolight, lactate and boerhavia diffusa root extract as active ingredients | |
| KR20030031697A (en) | Cosmetic Compositions Comprising Extract from Peach Blossom for Skin Whitening | |
| KR100678865B1 (en) | Cosmetic composition for skin whitening containing upper limb extract and carnitine as active ingredients | |
| KR101460901B1 (en) | Cosmetic composition for skin whitening, regeneration or moisturizing comprising amarogentin | |
| KR101006341B1 (en) | Cosmetic composition for skin whitening containing Myeongdangsam extract as an active ingredient | |
| KR100471685B1 (en) | Cosmetic Compositions Comprising Lactate and Ramulus Mori Extracts for Skin Whitening |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20030325 |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20050531 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20050929 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20051228 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20051228 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20080908 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20090907 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20100902 Start annual number: 6 End annual number: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20110811 Start annual number: 7 End annual number: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20120928 Year of fee payment: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20120928 Start annual number: 8 End annual number: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20131021 Year of fee payment: 9 |
|
| PR1001 | Payment of annual fee |
Payment date: 20131021 Start annual number: 9 End annual number: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20140925 Year of fee payment: 10 |
|
| PR1001 | Payment of annual fee |
Payment date: 20140925 Start annual number: 10 End annual number: 10 |
|
| FPAY | Annual fee payment |
Payment date: 20160927 Year of fee payment: 12 |
|
| PR1001 | Payment of annual fee |
Payment date: 20160927 Start annual number: 12 End annual number: 12 |
|
| FPAY | Annual fee payment |
Payment date: 20180918 Year of fee payment: 14 |
|
| PR1001 | Payment of annual fee |
Payment date: 20180918 Start annual number: 14 End annual number: 14 |
|
| FPAY | Annual fee payment |
Payment date: 20191119 Year of fee payment: 15 |
|
| PR1001 | Payment of annual fee |
Payment date: 20191119 Start annual number: 15 End annual number: 15 |
|
| PR1001 | Payment of annual fee |
Payment date: 20200925 Start annual number: 16 End annual number: 16 |
|
| PR1001 | Payment of annual fee |
Payment date: 20221011 Start annual number: 18 End annual number: 18 |
|
| PC1801 | Expiration of term |
Termination date: 20230925 Termination category: Expiration of duration |